Saturday 17 October 2026
Export NTLA’s income statement to Excel — free account
Intellia Therapeutics, Inc.
NTLA Healthcare Biotechnology
Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024. In the quarter to June 2026, revenue fell 46.2%, EPS grew 18.4% and free cash flow grew 15.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.42
0.08
+0.71%
Follow NTLA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
37.95 | 22.98 | 14.40 | 33.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(27.17) | (12.94) | (14.06) | (24.75) | |
P/B ratio |
3.10 | 2.45 | 1.45 | 2.54 | |
Price to Tangible BV |
3.10 | 2.45 | 1.45 | 2.54 | |
EV/Sales |
30.60 | 17.29 | 7.75 | 24.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.25) | (3.15) | (1.33) | (3.39) | |
EV/FCF |
(5.22) | (3.14) | (1.32) | (3.37) | |
Quick Ratio |
5.61 | 5.04 | 4.42 | 5.57 | |
Current Ratio |
6.65 | 6.10 | 5.08 | 6.21 | |
Net Debt/EBITDA |
3.96 | 3.82 | 4.85 | 4.80 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.08 | 0.07 | 0.05 | |
Operating CF/Net income |
0.78 | 1.22 | 0.72 | 0.76 | |
Capex/Depreciation |
(0.83) | (0.04) | (0.02) | (0.01) | |
Research and Development Expense of Revenue |
1,078.40% | 536.53% | 385.16% | 687.47% | |
Selling, General and Administrative Expense of Revenue |
493.85% | 231.55% | 143.70% | 221.39% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
236.00% | 89.57% | 72.72% | 142.24% | |
Graham Net Nets |
0.18 | 0.22 | 0.37 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.86%) | (27.61%) | (42.60%) | (24.72%) | |
Free Cash Flow Yield |
(15.43%) | (23.94%) | (40.63%) | (21.68%) | |
Revenue per Share |
0.06 | 0.13 | 0.21 | 0.13 | |
Operating CF per Share |
(0.62) | (0.99) | (0.64) | (0.70) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.64) | (0.99) | (0.64) | (0.70) | |
Cash per Share |
3.28 | 3.17 | 4.15 | 4.64 | |
Shareholders Equity per Share |
5.45 | 5.24 | 6.20 | 6.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.45 | 5.24 | 6.20 | 6.79 | |
Free Cash Flow |
(84.83) | (117.42) | (69.41) | (76.93) | |
Working Capital |
448.44 | 390.00 | 423.83 | 488.22 | |
Capital Expenditures |
(1.72) | (0.08) | (0.13) | (0.03) | |
Net Current Asset Value |
398.37 | 328.61 | 356.98 | 405.09 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.22 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.34 | 9.82 | 8.99 | 9.95 | |
Average Payables |
10.76 | 15.58 | 17.42 | 13.20 | |
Average Assets |
878.03 | 872.47 | 1,016.57 | 1,049.31 | |
Average Common Equity |
721.48 | 700.43 | 771.68 | 855.52 |
Columns are period end dates